title: [Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies].
abstract: BACKGROUND
  Antiangiogenic agents may be associated with severe hand-foot reactions (HFR) requiring dose adjustment by oncologists. Many preventive and curative treatments are described in the literature but their efficacy has not been assessed in clinical trials. The aim of this study was to examine information given to patients about HFR and to evaluate compliance with prophylactic therapy for this complication.
  
  
  METHODS
  Fifty-one patients receiving antiangiogenic therapy were followed up for a period of 19 months. At each visit, a dermatological examination was performed, compliance with topical treatment was assessed and advice was provided. At the end of the study, patients' perception of the information given was assessed by means of a questionnaire, completed either during consultations or by telephone.
  
  
  RESULTS
  Although all patients were given information about HFR, 11 of 39 subjects claimed they had received no such information. There was no difference regarding compliance with topical treatment whether the information was provided by a dermatologist or an oncologist. Eleven patients consulted a podiatrist and nine patients used soft insoles. Twenty-two of 40 patients used topical treatments, with nine using such treatment from the outset. A statistically significant correlation was noted between compliance with preventive topical therapy and onset of HFR (P=0.028), and this finding merits confirmation in a larger-scale study.
  
  
  CONCLUSIONS
  This study highlights the difficulties in implementing a programme to prevent HFR and suggests the value of providing multidisciplinary therapeutic education and of financing preventive and curative care.
authors: Service de dermatologie, hôpitaux de Brabois, CHU, bâtiment des spécialités médicales Philippe-Canton, rue du Morvan, 54500 Vandoeuvre-les-Nancy, France.
authors: P
authors: P
authors: Guyot-Caquelin
authors: L
authors: L
authors: Geoffrois
authors: A
authors: A
authors: Barbaud
authors: P
authors: P
authors: Trechot
authors: J-L
authors: JL
authors: Schmutz
authors: F
authors: F
authors: Granel-Brocard
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003880:Dermatology; D004643:Emollients / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D060831:Hand-Foot Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D008495:Medical Oncology; D055118:Medication Adherence; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009989:Orthotic Devices; D010353:Patient Education as Topic; D011032:Podiatry; D015397:Program Evaluation; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D011795:Surveys and Questionnaires
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D004643:Emollients; D007211:Indoles; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib